In the past few weeks, all the listed multi-national pharmaceutical companies have reported results for 2020, which has given us the opportunity to update our industry statistics and drug database. This report provides the first, snapshot publication of global and US rankings of the top 20 drug companies for 2020. Comparisons are made with historical data to show how different company strategies have evolved. In addition, summary analysis has been provided for the sales evolution of therapeutic biopharmaceutical drugs, which saw sales rise 5.6% to $245bn, representing 26% of the market, driven by antibody-derived drugs.

31 Mar 2021
The Monthly April 2021
Advanced Oncotherapy Plc (AVO:LON), 22.0 | Arix Bioscience Plc (ARIX:LON), 110 | BBGI Global Infrastructure S.A. SICAV -Ordinary- (BBGI:LON), 159 | City of London Investment Group PLC (CLIG:LON), 414 | Diurnal Group plc (DNL:LON), 11.0 | ICG Enterprise Trust PLC GBP (ICGT:LON), 0 | Oakley Capital Investments Limited (OCI:LON), 0 | Palace Capital plc (PCA:LON), 268 | Pantheon International (PIN:LON), 245 | Phoenix Copper Ltd. (United Kingdom) (PXC:LON), 34.0 | Real Estate Credit Investments Limited (RECI:LON), 149 | Shield Therapeutics Plc (STX:LON), 7.0 | Surface Transforms plc (SCE:LON), 44.0 | Surface Transforms plc (SCE:LON), 44.0 | Tissue Regenix Group plc (TRX:LON), 0 | Tissue Regenix Group plc (TRX:LON), 0 | Volta Finance Limited (VTA:LON), 545 | Pantheon International Plc (PIN:LON), 245
-
-
-
Hardman & Co Research Team
-
35 pages
-


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly April 2021
Advanced Oncotherapy Plc (AVO:LON), 22.0 | Arix Bioscience Plc (ARIX:LON), 110 | BBGI Global Infrastructure S.A. SICAV -Ordinary- (BBGI:LON), 159 | City of London Investment Group PLC (CLIG:LON), 414 | Diurnal Group plc (DNL:LON), 11.0 | ICG Enterprise Trust PLC GBP (ICGT:LON), 0 | Oakley Capital Investments Limited (OCI:LON), 0 | Palace Capital plc (PCA:LON), 268 | Pantheon International (PIN:LON), 245 | Phoenix Copper Ltd. (United Kingdom) (PXC:LON), 34.0 | Real Estate Credit Investments Limited (RECI:LON), 149 | Shield Therapeutics Plc (STX:LON), 7.0 | Surface Transforms plc (SCE:LON), 44.0 | Surface Transforms plc (SCE:LON), 44.0 | Tissue Regenix Group plc (TRX:LON), 0 | Tissue Regenix Group plc (TRX:LON), 0 | Volta Finance Limited (VTA:LON), 545 | Pantheon International Plc (PIN:LON), 245
- Published:
31 Mar 2021 -
Author:
Hardman & Co Research Team -
Pages:
35 -
In the past few weeks, all the listed multi-national pharmaceutical companies have reported results for 2020, which has given us the opportunity to update our industry statistics and drug database. This report provides the first, snapshot publication of global and US rankings of the top 20 drug companies for 2020. Comparisons are made with historical data to show how different company strategies have evolved. In addition, summary analysis has been provided for the sales evolution of therapeutic biopharmaceutical drugs, which saw sales rise 5.6% to $245bn, representing 26% of the market, driven by antibody-derived drugs.